Vivesto Ab · OMXSTO:VIVE
Vivesto Ab — Oasmia Pharmaceutical — BIO-Europe Spring 2021
20 slides from Vivesto Ab's conference presentation, Mar 25, 2021
Slide 1: BIOEUROPE SPRING
BIOEUROPE SPRING F.R. Martelet, M.D., CEO 22 – 25 March 2021 1
Slide 2: Forward-looking statement
Forward-looking statement IMPORTANT NOTICE The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require p
Slide 3: Oasmia – an innovation-focused specialty pharmaceutical company
Oasmia – an innovation-focused specialty pharmaceutical company Growing pipeline, focused on Significant in-/out-licensing Oncology and with potential in other & M&A opportunities to drive therapeutic areas growth XR-17™ technology platform to enhance intravenous delivery of Lean and agile establish
Slide 4: A clearly defined strategy to support future growth
A clearly defined strategy to support future growth 1 2 3 4 Execute on Apealea® Enhancement & Clinical development In- & out-licensing, global partnership partnering of of Docetaxel partnering & M&A with Elevar technology platforms micellar in oncology • US regulatory pathway • Work underway to pote
Slide 5: Apealea® – an improved treatment option in ovarian cancer
Apealea® – an improved treatment option in ovarian cancer 1 Solvent-free IV formulation of paclitaxel • No polyoxyethylated castor oil or dehydrated alcohol • No glucocorticosteroids required pre- medication • Shorter infusion and overall ‘chair’ time Approved in EU for treatment of first relapse ov
Slide 6: Maximizing Apealea® – leveraging our global agreement with Elevar
Maximizing Apealea® – leveraging our global agreement with Elevar 1 Nordic states Peak sales • Oasmia commercializing estimates ~$275m - $282m (ovarian Europe (excluding Nordics) cancer1) USA • Commercialization agreement signed • Pathway to commercialization identified between Elevar Therapeutics a
Slide 7: XR-17™ – tackling poor drug solubility
2 XR-17TM – tackling poor drug solubility POOR API1 AFFECTS c.40% OF IMPLICATED IN SERIOUS A SIGNIFICANT PROBLEM FOR PATIENTS SOLUBILITY APPROVED DRUGS2 ADVERSE EVENTS AND PHARMA COMPANIES Major challenge in 70-90% of pipeline Solubility enhancers $180 bn SPENT ON drug development drugs classed as c
Slide 8: XR-17™ – targeting improved safety and efficacy
2 XR-17™ – targeting improved safety and efficacy High drug delivery capability Cancers: Shorter infusion time1,2 Ovarian Superior solubility Prostate Enhanced API bioavailability Bladder Validated safety in cancer 1 Lung No or limited need for pre-medication1 Breast No alcohol, Crem. EL, Polys.80,
Slide 9: Expanding our technologies
2 Expanding our technologies Project Objective Discovery Feasibility Development Validation Launch Solubilization platform XR-17™ Out licensing and sales Next generation of XR-18 XR-17 Target 2023 Out licensing and sales Solubilization platform XR-19 – dual encapsulation Target 2022 Out licensing an
Slide 10: Docetaxel micellar – phase 1b in prostate cancer to begin H1 2021
3 Docetaxel micellar – phase 1b in prostate cancer to begin H1 2021 • Phase 1b trial to be initiated by 1 in 7 SAKK (Swiss Group for Clinical men will be Cancer Research) diagnosed with • Protocol evaluation review prostate underway cancer ‒ Docetaxel approved for wide range of solid malignancies ‒
Slide 11: Actively seeking in-licensing opportunities & collaborations
4 Actively seeking in-licensing opportunities & collaborations • We want to in-license oncology products from pre-clinical up to late Phase 3 development Registration / Pre-clinical Phase 1 Phase 2 Phase 3 approval Marketed • We’re also pursuing collaborations to support partners’ R&D and overcome s
Slide 12: Cantrixil – building critical mass in our oncology pipeline
4 Cantrixil – building critical mass in our oncology pipeline • Global rights to drug candidate Cantrixil (INN/TRX-E002-1) licensed from Kazia Therapeutics Limited (ASX:KZA) • Builds on Oasmia’s proven development and regulatory expertise in ovarian cancer • Evaluating potential for synergies with A
Slide 13: Cantrixil – first-in-class ovarian cancer therapy with strong Phase 1 data
4 Cantrixil – first-in-class ovarian cancer therapy with strong Phase 1 data • Tubulin-binding small molecule with potent cytotoxicity against CD 44+ ovarian cancer stem cells, ovarian somatic cancer cells (CD 44+), both resistant to standard chemotherapies ‒ Potential to improve outcome in relapsed
Slide 14: A rapidly growing clinical-stage portfolio
A rapidly growing clinical-stage portfolio Registration / Commercial Product Indication Pre-clinical Phase 1 Phase 2 Phase 3 approval Launch Geography Human Health Portfolio Apealea® / Ovarian cancer EU / EEA Paclical® (paclitaxel) Ovarian cancer USA Cantrixil Ovarian cancer Global Docetaxel Prostat
Slide 15: Focusing resources – strong cash position & reduced cash burn rate
Focusing resources – strong cash position & reduced cash burn rate 1,2 • Cash and cash equivalents & short-term investments TSEK 287,405 (325,658) • Consolidated net sales TSEK 482 (565) • Operating profit/loss TSEK -131,493 (-117,256) • Cash burn to reduce over the next two years to 10-12 MSEK per
Slide 16: The right team for success
The right team for success FRANCOIS MARTELET, FREDRIK JÄRRSTEN* DR HEIDI B. RAMSTAD, REINHARD KOENIG, M.D. ELIN TRAMPE, M.A. PETER SELIN, B.Sc. M.D., Master’s Degree Business Chief Finance Officer M.D. Acting Chief Scientific Chief Technical Officer Chief Business Officer Chief Executive Officer Chi
Slide 17: Sustained transformation & delivery since March 2020
Sustained transformation & delivery since March 2020 Clearly defined strategy for growth 2021 onwards Maximizing Apealea® Opportunity to build a sustainable, profitable specialty pharma company Building the pipeline through in-house R&D, M&A, and in-licensing of clinical assets Focusing resources Se
Slide 18: Looking ahead – multiple catalysts to drive near-term value
Looking ahead – multiple catalysts to drive near-term value Potential near- and mid-term value drivers • Apealea® - partnering by Elevar in key territories; milestone payments & royalties • Docetaxel micellar - Phase 1b initiation by SAKK • Cantrixil – trial design, KOL recruitment and supply organi
Slide 19: Delivering on our four-pillar strategy for growth
Delivering on our four-pillar strategy for growth 1 2 3 4 Execute on Apealea® Enhancement & Clinical development In- & out-licensing, global partnership partnering of of Docetaxel partnering & M&A with Elevar technology platforms micellar in oncology
Slide 20: Thank you!
Thank you! Oasmia Pharmaceutical AB (STO: OASM) +46 018-50 54 40 www.linkedin.com/comp Vallongatan 1 any/oasmia- 752 28 Uppsala IR@oasmia.com pharmaceutical-ab Sweden www.oasmia.com www.twitter.com/Oasmia